EAN 2021 | Biomarkers as a diagnostic tool for Alzheimer’s disease

Wiesje van der Flier • 8 Jun 2021

EAN 2021

Wiesje van der Flier, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses how advances in biomarker research are leading to improvements in the diagnosis of Alzheimer’s disease. Prof. van der Flier explains how past breakthroughs in biomarker research, such as discovering the presence of amyloid and tau in the cerebrospinal fluid (CSF), led to improvements in diagnostics and discusses how current research into blood-based biomarkers could lead to further progress. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, Stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape). WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in an advisory board of Biogen MA Inc. WF is associate editor at Alzheimer’s, Research & Therapy. All funding is paid to her institution.